Lynx1 Capital Management LP insider trades

Open-market stock purchases and sales by Lynx1 Capital Management LP, 10% Owner at Passage BIO, Inc, from SEC Form 4 filings since May 31, 2023.

Track record: 54% of 24 scored buys are up 5% or more since purchase, averaging +9%.

Recent trades

DateStockTradeValue
Jun 25, 2026PASG Passage BIO, IncBought$206K
Mar 31, 2026KRRO Korro Bio, IncBought$5.5K
Dec 23, 2025TCRX TScan Therapeutics, IncBought$5.6K
Dec 22, 2025TCRX TScan Therapeutics, IncBought$68K
Dec 19, 2025TCRX TScan Therapeutics, IncBought$72K
Oct 28, 2025CGEM Cullinan Therapeutics, IncBought$1.4M
Oct 21, 2025NEUP Neuphoria Therapeutics IncBought$3.3M
Oct 17, 2025CGEM Cullinan Therapeutics, IncBought$253K
Oct 16, 2025CGEM Cullinan Therapeutics, IncBought$1.3M
Oct 15, 2025CGEM Cullinan Therapeutics, IncBought$409K
Oct 14, 2025CGEM Cullinan Therapeutics, IncBought$114K
Oct 10, 2025CGEM Cullinan Therapeutics, IncBought$2M
Oct 9, 2025CGEM Cullinan Therapeutics, IncBought$4.2M
Oct 8, 2025CGEM Cullinan Therapeutics, IncBought$3.6M

Companies traded

  • PASG Passage BIO, Inc: 11 buys, last Jun 25, 2026
  • KRRO Korro Bio, Inc: 1 buy, last Mar 31, 2026
  • TCRX TScan Therapeutics, Inc: 10 buys, 3 sales, last Dec 23, 2025
  • CGEM Cullinan Therapeutics, Inc: 8 buys, last Oct 28, 2025
  • NEUP Neuphoria Therapeutics Inc: 1 buy, last Oct 21, 2025

Get free alerts when Lynx1 Capital Management LP files a new trade →